A year after unveiling its first blood test aimed at spotting the signs of a range of neurodegenerative diseases, Labcorp is ramping up its offerings in that realm with the launch of a new, ...

In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying ...

BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 ...

BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo for Labcorp is displayed on a screen on the floor of the NYSE in New York By Deena Beasley (Reuters) - ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Labcorp Holdings (NYSE:LH) launched the first FDA cleared ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min As the number of Americans at ...

BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® ...